Cerebral Therapeutics

Early-stage drug delivery company developing Intracerebroventricular (ICV) delivery methods for Valproate for the treatment of neurological diseases such as epilepsy.

placeAurora, Colorado, United States calendar_todayFounded 2010 groups19 employees language cerebraltherapeutics.com

Innovation

15 patent families (3 granted) — focus: Human necessities; filing pace slowing. Cited 302 times.

YearFilings
20182
20194
20203
20227
20239
20244

Investor mix

6 investors on record; lead investors include RA Capital Management, Vivo Capital, Granite Point Capital, Lynx Capital.

Investor typeCountShare
Venture capital233%
Private equity117%
Other / undisclosed350%
Coming soon